Bladder Urachal Adenocarcinoma
Bladder urachal adenocarcinomas most frequently harbor alterations in TP53, KRAS, STK11, SMAD4, and NF1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KRAS Mutation, and TP53 Nonsense are the most common alterations in bladder urachal adenocarcinoma .
There is 1 clinical trial for bladder urachal adenocarcinoma, of which 0 are open and 1 is completed or closed. Of the trial that contains bladder urachal adenocarcinoma as an inclusion criterion, 1 is phase 2 (0 open).
Durvalumab and tremelimumab are the most common interventions in bladder urachal adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.